Newbridge Financial Services Group Inc. Takes Position in Coya Therapeutics, Inc. (NASDAQ:COYA)

Newbridge Financial Services Group Inc. bought a new stake in Coya Therapeutics, Inc. (NASDAQ:COYA) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 70,000 shares of the company’s stock, valued at approximately $401,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of Coya Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after buying an additional 4,485 shares in the last quarter. GHP Investment Advisors Inc. acquired a new stake in Coya Therapeutics in the 3rd quarter valued at $169,000. Finally, Renaissance Technologies LLC purchased a new stake in Coya Therapeutics in the 2nd quarter worth $101,000. 39.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on COYA shares. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday. D. Boral Capital restated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, November 11th.

Coya Therapeutics Stock Down 2.4 %

Coya Therapeutics stock opened at $6.83 on Monday. The company has a fifty day simple moving average of $5.87 and a 200-day simple moving average of $6.39. The firm has a market capitalization of $114.11 million, a price-to-earnings ratio of -10.51 and a beta of 0.47. Coya Therapeutics, Inc. has a 52-week low of $4.75 and a 52-week high of $10.69.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.